Freneslerbart/mevonlerbart

Monoclonal antibody

Also known as REGN1908, REGN1909

Phase 3underway

Evidence outlook · registrational

Allergic Conjunctivitis: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-05-31.

Also in development:Cat Allergy · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Allergic Conjunctivitis
NCT07675811 · Regeneron Pharmaceuticals
2026-07-31 – 2029-09-20 · Allergic Conjunctivitis
What this study did
NCT06602726 · Regeneron Pharmaceuticals
2024-11-06 – 2025-08-02 · Allergic Conjunctivitis
What this study did
Cat Allergy
NCT04981717 · Regeneron Pharmaceuticals
2021-07-30 – 2023-04-24 · Allergic Rhinitis Due to Cat Allergy
What this study did
Phase 2 (1)
Cat Allergy
Phase 1 (2)
Other / comorbidity
NCT02127801 · Regeneron Pharmaceuticals
2014-10-31 – 2015-12-31 · Allergy
What this study did
NCT01922661 · Regeneron Pharmaceuticals
2013-08 – 2014-05 · Allergy
What this study did

Competitive landscape

This drug's own stage for Allergic Conjunctivitis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Freneslerbart / Mevonlerbart: this drugPhase 3Monoclonal antibodyFel d 1 (major cat allergen protein)not yet gradedNo reviewed efficacy summary in this indication
Dexamethasone (Dextenza)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ReproxalapPhase 3Small moleculeReactive aldehyde species (RASP)Partial signalFeatured results are non-efficacy only in this race

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Freneslerbart/mevonlerbart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
May 2029 (1)
Phase 3Allergic ConjunctivitisRecruiting
Est. primary completion 2029-05-31 · NCT07675811 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2025Topline resultPhase 3 cat-allergy ocular challenge trial (NCT06602726) met its primary endpoint
Regeneron Pharmaceuticals, Inc. · Source ↗